Versant Capital Management, Inc Biocryst Pharmaceuticals Inc Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 154 shares of BCRX stock, worth $1,349. This represents 0.0% of its overall portfolio holdings.
Number of Shares
154Holding current value
$1,349% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
294Shares Held
177MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$190 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$175 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$78.2 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$76.2 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$68.4 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.63B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...